Recon: FDA approves Roche’s Polivy for first-line lymphoma treatment; Bristol pays Tubulis up to $1B to deepen ADC pipeline
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy